What is Protier Biotech?
Protier Biotech is a pioneering biotechnology firm dedicated to developing next-generation therapies for incurable diseases, with a pronounced emphasis on cancer treatment. The company leverages specialized platforms in molecular glue degraders and targeted protein degradation to engineer innovative, patient-centric drugs. Its core mission is to enhance survival outcomes and propel the field of precision medicine forward through groundbreaking therapeutic solutions.
How much funding has Protier Biotech raised?
Protier Biotech has raised a total of $2.5M across 1 funding round:
Other Financing Round
$2.5M
Other Financing Round (2026): $2.5M with participation from Hana Ventures, Korea Investment Partners Us, and Tinvestment
Key Investors in Protier Biotech
Hana Ventures
Hana Ventures is a financial company that collaborates with ventures to provide innovative financial solutions, aiming to support startups and emerging businesses by offering tailored financial services and investment guidance.
Korea Investment Partners Us
Korea Investment Holdings is a leading financial holding company in South Korea, primarily focused on investment banking, offering a range of financial services through its subsidiaries and committed to sustainable management.
Tinvestment
Tinvestment operates within the Electronics industry, employing between 10 to 19 people and generating between $1M to $5M in revenue, indicating a focus on technology and innovation.
What's next for Protier Biotech?
The substantial enterprise-level funding and recent strategic investment position Protier Biotech for accelerated growth and the scaling of its innovative therapeutic platforms. This capital infusion is expected to fuel further research and development, clinical trials, and the expansion of its operational capabilities. The company's focus on molecular glue degraders and targeted protein degradation suggests a strategic push towards highly specific and effective treatments, potentially marking a new era in oncology and rare disease therapies.
See full Protier Biotech company page
